MJH Life Sciences to Offer Free Webinar on COVID-19 Vaccine Progress

July 28, 2020

Experts will examine the prospects of several COVID-19 vaccine candidates that are entering phase 3 trials.

MJH Life Sciences™ is offering a free webinar covering potential vaccines for the novel coronavirus disease 2019 (COVID-19) on July 30 at 6 p.m. Eastern Daylight Time (EST).

As the death toll of the COVID-19 coronavirus pandemic rises above 136,000 Americans and more than 4 million Americans have tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, the country awaits the development of a vaccine and the end of the COVID-19 pandemic.

With the advancing development of a vaccine, and with legislation already being passed allowing pharmacists to administer a COVID-19 vaccine, the United States’ most accessible health care professionals must remain preparedand informed on budding phase 3 trials and leading research. The webinar will also discuss how to combat logistical challenges associated with rolling out a vaccine in the middle of a pandemic.

The 1-hour webinar will confront the race for a vaccine and feature experts on viruses and vaccines who will delve into the research at the forefront of COVID-19 vaccine development.

Click here to register for the free event

The panel for this webinar features:

  • Walter A. Orenstein, MD, professor of medicine, pediatrics, global health, and epidemiology at Emory University, and director of the Emory Vaccine Center; spent 26 years with the U.S. Immunization Program at the Center for Disease Control and Prevention. His research focuses on vaccine effectiveness and uptake.
  • Angela Rasmussen, PhD, is a virologist studying host responses to infection by combining classical virology with a modern systems biology approaches. Her research focuses on identifying host response signatures predictive of infection severity or disease outcome and host pathways to target drug development or repurposing.
  • Gregory A. Poland, MD, studies the immunogenetics of vaccine response in adults and children. Along with his team within the Vaccine Research Group, his aim is to improve the health of individuals across the world by pursuing challenges posed by infectious diseases and bioterrorism through clinical, laboratory, and epidemiologic vaccine search.